

---

---

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

*For the month of July 2015*

---

**BioLineRx Ltd.**

(Translation of registrant's name into English)

---

**Modi'in Technology Park  
2 HaMa'ayan Street  
Modi'in 7177871, Israel**  
(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F**       **Form 40-F**

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

**Yes**       **No**

---

On July 16, 2015, the Company filed a shelf registration statement on Form F-3. This shelf registration is intended as a renewal of an existing shelf registration which was filed in August 2012 and which will expire in August 2015. It is the Company's policy to continuously maintain an effective shelf registration statement.

This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioLineRx Ltd.**

By: /s/ Philip Serlin

Philip Serlin  
Chief Financial and Operating Officer

Dated: July 16, 2015

---